No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Recent Posts
- TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
- TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
- TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
- TuHURA Biosciences Completes Acquisition of Kineta
- TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
Recent Comments
No comments to show.